GMP fixes questioned in India vax plant restarts

The closing of three state-run vaccine plants in India appears to have been both preceded and followed by hasty decision-making. The shuttering of the aging facilities followed the finding of violations of WHO manufacturing practices.

The plant licenses were revoked in January 2008, and a new report by a parliamentary panel says a rehab and reopening of the plants was "not envisaged by the government." Yet a health official last March asked the government to restart the facilities "immediately" and bring them up to quality standards, as reported. Two of the plants were in operation as of last month, as reported, with the third well on its way.

But the parliamentary report writers say the central government has no roadmap to revive the plants. And a local press report finds that, despite the restarts, the government is "still not serious" about resolving the GMP matters.

- see the article


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.